… efficient Cyclic Dependent Kinase inhibitors is progressively … of cyclic dependent Kinase
inhibitors with insights into their … CDK2 inhibitors 3a and 3b and the best anti-tumor agents 3c …

… These processes include alterations in cellular metabolism, anti-tumor immune responses,
… of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response. …

… cyclin-dependent kinases (CDKs) and their cognate cyclins, along with their endogenous
inhibitors … Progress in the evaluation of CDK inhibitors as antitumor agents. Drug Discov. Today…

The introduction of cyclin-dependent kinase 4/6 inhibitors (CKIs) has marked a major
development in the standard treatment of advanced breast cancer. Extensive preclinical, …

… SY-1365, a CDK7 inhibitor has shown initial encouraging data in phase I for solid tumors …
inhibitor research since 2015 to 2019, with special emphasis on transcriptional CDK inhibitors, …

… The potent anti-tumor effects of palbociclib have been observed in several tumor types, … a
switch to a new agent, rather than continuing CDK4/6 agents beyond progression. Moreover, …

… Recent studies on cyclin-dependent kinase (CDK) inhibitors have revealed that small
molecule drugs have become very attractive for the treatment of cancer and neurodegenerative …

… THZ1 has facilitated the CDK7-related studies, and recent findings highlighted the potential
of CDK7 as anti-tumor as well as anti-HIV drug target [Citation8–10]. Subsequently, several …

… agents, with an emphasis on novel agents and potential new indications for this drug class.
… Early phase Ib results showed that the combination is safe and has anti-tumor efficacy in …

… by inhibitors after this phase and then combined with the corresponding chemotherapy drugs,
a … strategy involving CDK inhibitors and other anti-tumor drugs should be further explored. …